Previous studies have indicated that the mRNA‐encoding amyloid precursor protein (APP) is one of the direct binding targets of FMRP; this led to the discovery that impaired APP expression might contribute to the deficits seen in FXS (Westmark et al., 2016). The gene discussed is APP; the disease is fragile X syndrome.